The Goldman Sachs Group Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $917.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lowered by The Goldman Sachs Group from $1,019.00 to $917.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Citigroup lowered their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Finally, UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $964.88.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $571.06 on Monday. The company has a market cap of $62.43 billion, a price-to-earnings ratio of 14.92, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals has a 1 year low of $525.99 and a 1 year high of $1,211.20. The stock’s 50 day simple moving average is $657.03 and its two-hundred day simple moving average is $749.93. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $11.86 earnings per share. As a group, equities analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently made changes to their positions in REGN. Harbor Capital Advisors Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $981,000. Tounjian Advisory Partners LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $662,000. Pallas Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $426,000. Farther Finance Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 9.6% in the 1st quarter. Farther Finance Advisors LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $387,000 after purchasing an additional 55 shares in the last quarter. Finally, Daymark Wealth Partners LLC lifted its position in shares of Regeneron Pharmaceuticals by 52.5% in the 1st quarter. Daymark Wealth Partners LLC now owns 523 shares of the biopharmaceutical company’s stock worth $332,000 after purchasing an additional 180 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.